Vortioxetine in the Treatment of Major Depressive Disorder Among Working Patients in Routine Clinical Practice: An Analysis of a Post-Marketing Surveillance Study in South Korea
Seok Woo Moon,Jee Wook Kim,Do Hoon Kim,Michael Adair,Daniel Åström,Elin Reines,Minah Lee,Gayoung Kim
DOI: https://doi.org/10.2147/ndt.s478804
IF: 2.989
2024-11-28
Neuropsychiatric Disease and Treatment
Abstract:Seok Woo Moon, 1 Jee Wook Kim, 2 Do Hoon Kim, 3, 4 Michael Adair, 5 Daniel Oudin Åström, 6 Elin Heldbo Reines, 5 Minah Lee, 7 Gayoung Kim 7 1 Department of Psychiatry and Research Institute of Medical Science, Konkuk University School of Medicine, Chungju, South Korea; 2 Department of Neuropsychiatry, Hallym University Dongtan Sacred Heart Hospital, Dongtan, Korea; 3 Department of Psychiatry, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea; 4 Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon, Korea; 5 Department of MSC Vortioxetine & Established Products, H. Lundbeck A/S, Valby, Denmark; 6 Department of Real-World Evidence & Epidemiology, H. Lundbeck A/S, Valby, Denmark; 7 Department of RA&MA, Lundbeck Korea Co., Ltd., Seoul, Korea Correspondence: Seok Woo Moon, Department of Psychiatry and Research Institute of Medical Science, Konkuk University School of Medicine, 82 Gugwon-daero, Chungju-si, Chungcheongbuk-do, 27376, South Korea, Tel +82-10-3276-1641, Email Background: Patients with major depressive disorder (MDD) experience depressive symptoms such as anhedonia as well as cognitive dysfunction which can subsequently impair their work performance. Purpose: To assess the effectiveness and safety of vortioxetine in working patients with MDD in South Korea. Patients and Methods: This was a subgroup analysis of a prospective, multicenter, non-interventional, non-comparative post-marketing surveillance (PMS) study. Vortioxetine-naïve patients aged > 18 years who were administered with vortioxetine were followed for up to 24± 2 weeks. Working patients were defined as those who were working or studying full- (≥ 6 hours/day) or part-time (< 6 hours/day) at baseline. Effectiveness and adverse events (AEs), assessed by both clinician and patient-reported measured, were analyzed. Results: A total of 1082 working patients (mean age: 39.56 years) were included in the subgroup analysis. Clinically significant improvements in depressive symptoms, including anhedonia, were observed over the 24 weeks of follow-up, with mean scores for the total Montgomery-Asberg Depression Rating Scale (MADRS) and anhedonia subscale both significantly decreasing from baseline by mean±standard deviation (SD) of 9.73± 9.08 and 5.37± 5.24 points, respectively, at 24 weeks (both p< 0.001 vs baseline). The vast majority of patients (80.01%) treated with vortioxetine also showed improvements in mental health symptoms over the 24 weeks, measured using the Clinical Global Impression – Improvement (CGI-I) scores. Significant improvements in cognitive symptoms were also observed over the study period, measured by the Korean Version of the Perceived Deficits Questionnaire-Depression as well as Digit Symbol Substitution Test (all p< 0.0001 from baseline at Visits 2 and 3). Vortioxetine was well tolerated in working patients, with the respective rates of any AEs and serious AEs being 18.67% and 1.20%. Conclusion: Working patients treated with vortioxetine had improvements in their depressive symptoms (including anhedonia), cognitive function and performance. Vortioxetine was found to be well tolerated in this study. Keywords: major depressive disorder, non-interventional, post-marketing surveillance, South Korea, vortioxetine, work performance Major Depressive Disorder (MDD) is a common psychiatric disorder in adults, with approximately 5% of adults having experienced depression globally. 1 MDD is one of the leading causes of health burden among the working-age population worldwide. 2,3 In 2019, depressive disorders were the 6 th highest cause of burden, measured using disability-adjusted life years, among those aged 25–49 years. 2,3 In South Korea, the burden of MDD is also increasing; between 1990 and 2017, South Korea had the 3 rd highest increase in age-standardized incidence of MDD among 195 countries. 4 MDD is associated with cognitive symptoms that have detrimental impacts on work performance, such as reduced work productivity and increased sick leave. Such adverse work-related outcomes due to MDD could pose substantial economic burden personally and to society. A modelling study in South Korea reported that MDD was estimated to result in 11,740 excess deaths in people of working age when compared with those without MDD, which translated to 55,126 years of life lost due to MDD. 5 The same study estimated that 1,627,333 productivity-adjusted life years were lost in the MDD cohort compared with those without MDD, equating to loss of appr -Abstract Truncated-
psychiatry,clinical neurology